By goalWeight loss · Muscle building · Healing and recovery · Skin and cosmetic · Brain, mood and sleep · Longevity and energy · Sexual and hormonal · Immune support · All groups
383 compounds·36 are non-peptides commonly sold alongside peptides.
The Ozempic and Wegovy drug: a weekly shot that turns up your 'I'm full' signal so you eat less.
The Mounjaro and Zepbound drug: a weekly shot that works two appetite and blood-sugar signals at once.
A weekly shot that copies three fullness and fat-burning signals, with some of the largest weight losses in trials.
A weekly shot that copies amylin, a different fullness hormone from GLP-1. Often paired with semaglutide.
The Saxenda and Victoza drug: the same fullness signal as semaglutide, shorter-acting and taken daily.
Copies your fullness signal and pushes metabolism to burn more. Trials show weight loss and better fatty liver.
Works on appetite and metabolism together, much like survodutide. Approved in China, in trials elsewhere.
Two different 'stop eating' signals, GLP-1 and amylin, built into one molecule. Tested as a pill and as a shot.
Works the same two appetite signals as tirzepatide. In trials as both a shot and a pill.
A GLP-1 pill that survives digestion, so there are no needles and no empty-stomach rule.
Not a peptideA mealtime shot taken with insulin in diabetes. Blunts the blood-sugar spike after eating and reduces hunger.
A growth hormone fragment built to keep the fat-burning effect and drop the rest. Human proof that it works is weak.
The tail end of growth hormone, the part linked to fat breakdown. Human evidence is thin.
Blocks NNMT, an enzyme that helps fat cells store fat. Studied for fat loss and energy on very little human data.
Not a peptideSuppresses hunger through the brain's reward system, the way a stimulant does, and carries more heart risk for it.
Not a peptideNicknamed 'exercise in a molecule' for pushing cells to act as if you had worked out. There is no human data yet.
Not a peptideA short peptide your own mitochondria make. Signals cells to burn more fuel, explored for metabolism and aging.
Cagrilintide and semaglutide in one weekly shot, hitting two separate fullness pathways at once.
A GLP-1 pill whose development was stopped over a liver-injury signal.
Not a peptideA long-acting copy of amylin, the pancreas's fullness hormone, positioned as a gentler standalone option.
An amylin copy tuned to hit the amylin receptor about 14 times harder than the calcitonin receptor.
Restores the missing 'I'm full' signal in people with rare genetic defects in one hunger pathway.
An antibody carrying two GLP-1 peptides that also blocks the GIP receptor. Injected once a month.
A weekly shot that works the same two appetite signals as tirzepatide.
Curbs appetite and pushes metabolism to burn more. Studied for weight loss and fatty-liver disease.
Eli Lilly's copy of amylin, the pancreas's fullness hormone, designed to be easy to tolerate.
GLP-1 appetite control built to last long enough for one injection a month.
An antibody that blocks a signal limiting muscle. Studied with GLP-1 drugs to add muscle while fat comes off.
Signals your pituitary to release a pulse of your own growth hormone, with little effect on hunger or stress hormones.
A copy of the hormone that triggers growth hormone, with an anchor (the DAC) that keeps it working for days.
The short-acting version: a quick growth hormone pulse that clears fast. Usually paired with ipamorelin.
Two growth hormone signals in one vial. The CJC-1295 is almost always the no-DAC kind, also sold as Mod GRF 1-29.
A shortened copy of the hormone that prompts growth hormone release. Gentler than injecting the hormone itself.
Raises your own growth hormone and is proven to shrink deep belly fat. Approved for HIV-related belly fat.
A stronger growth hormone pulse than ipamorelin, with some rise in appetite and stress hormones.
Raises your own growth hormone and triggers intense hunger, so it is mostly used for bulking.
A potent growth hormone releaser. The body adapts to it quickly, so it stops working well with continued use.
A daily pill that keeps growth hormone and IGF-1 raised around the clock, with no injections.
Not a peptideLab-made growth hormone itself, injected directly. The most powerful option, the priciest, and prescription-only.
A long-acting form of the hormone growth hormone works through. Drives muscle growth and drops blood sugar hard.
A short, extra-potent IGF-1 that acts where it is injected, then clears quickly.
Blocks myostatin, the body's brake on muscle growth. Dramatic in animals, experimental in people.
An IGF-1 variant muscles make after hard exercise. Activates the stem cells that rebuild muscle.
MGF with a PEG coating that makes it last far longer, so the same repair job runs on a less frequent schedule.
A decoy receptor that soaks up the signals limiting muscle. Development was paused over side effects.
A 15-amino-acid chain based on a stomach protein, used after injuries. Almost all the evidence is from animals.
A fragment of the repair protein thymosin beta-4, used for muscle and tendon healing. Most evidence is from animals.
A very new arginate-salt cousin of BPC-157, aimed at the same repair job with more stability.
Three peptides in one vial: GHK-Cu for skin, plus BPC-157 and TB-500 for tissue repair.
The GLOW blend (GHK-Cu, BPC-157, TB-500) with KPV added for anti-inflammatory effect.
The three-amino-acid tail of the hormone alpha-MSH, sold to calm gut and skin without tanning. No human trials exist.
Carved from EPO to keep its repair signal without thickening the blood. Reached human trials for nerve pain.
A natural signal that relaxes airways and calms the immune system. Used as a nasal spray, and can lower blood pressure.
Tightens the junctions between gut-lining cells. Studied mainly for celiac disease, and not absorbed into the body.
Acts like the natural lubricant in joints and the bladder lining. Used for arthritis and painful bladder.
Not a peptideUsed for focus and memory, and in Russia after strokes. The human studies use the nasal route, not injection.
Used for anxiety without sedation. The human studies and the Russian approval use the nasal route, not injection.
A chemically modified Semax, built to resist breakdown and last longer.
A natural brain peptide linked to deep sleep, taken before bed. Results are inconsistent.
A mix of small peptides from pig brain tissue, with the strongest human evidence in its group for stroke and dementia.
Studied for building new brain connections and reversing memory loss. Striking in animals, almost no human safety data.
A century-old dye taken at low doses for focus and energy. It turns urine blue-green, and that is harmless.
Not a peptideA 3-amino-acid Khavinson peptide sold for brain function, sleep and aging, with very little human research.
Derived from a natural nerve-growth factor. Studied for growing new brain cells, with no human data.
Blocks a potassium channel tied to mood. Studied as a fast-acting antidepressant, with no human data.
A 4-amino-acid Khavinson peptide taken in short courses for sleep and aging. Human evidence is thin.
A coenzyme every cell uses to make energy, with levels that fall with age. Evidence for injecting it is still early.
Not a peptideStabilizes the inner wall of mitochondria so damaged ones make energy again. Approved in 2025 for Barth syndrome.
A short peptide encoded in mitochondrial DNA that acts as a cell-protection signal. Human data is limited.
Designed to make worn-out 'zombie' cells self-destruct. Striking in animals, almost no human safety data.
A thymus extract taken in short courses for immune function and aging. Western human evidence is limited.
A 2-amino-acid Khavinson peptide sold for immune balance and aging, with very little human research.
A short Khavinson peptide based on a brain-tissue peptide, taken for nerve recovery on very little human research.
A 3-amino-acid Khavinson peptide sold for cartilage and joints, with very little human research.
A 3-amino-acid Khavinson peptide sold for blood-vessel health with age, with very little human research.
A 4-amino-acid Khavinson peptide sold for lung and airway health, with very little human research.
A short Khavinson peptide sold for liver and digestive support, with very little human research.
A 3-amino-acid Khavinson peptide sold for lung and gut-lining support, with very little human research.
A Khavinson bioregulator drawn from nerve tissue, sold for brain and nerve support on very little human research.
A Khavinson bioregulator drawn from cartilage, sold for bone and joint health on very little human research.
The body's main antioxidant, a three-amino-acid peptide. Taken for skin brightness and detox support.
A thymus peptide that helps direct immune defenses. Well studied, and used abroad as an add-on therapy.
Part of your own first-line immune defense. Punches holes in bacteria and helps wounds heal, on limited human data.
A zinc-dependent thymus peptide studied for immune balance, inflammation and pain. Human data is limited.
A 2-amino-acid thymus peptide from the Khavinson family, taken in courses for immunity on very little human research.
Raises sexual desire through brain signaling, not blood flow. Approved for low libido in women.
Sits at the top of the reproductive hormone chain and switches on your body's own sex-hormone production.
Prompts your own testosterone and fertility hormones. It clears fast, so it needs frequent dosing.
Mimics the signal telling the testicles to make testosterone and sperm. Used with testosterone therapy or for fertility.
Supplies FSH and LH, the two hormones that drive egg and sperm production. Used in fertility treatment.
The 'bonding hormone', used as a nasal spray or tablet for connection and mood. Effects are subtle and short-lived.
A copper-binding peptide your body uses in tissue repair. On skin it signals collagen, hence its place in skincare.
Tells skin to make pigment for a slow, even tan. Approved as Scenesse for a rare light-sensitivity disorder.
Tans skin fast and also raises libido and cuts appetite. Hitting that many receptors brings more side effects.
Mildly limits the signal muscles use to contract. On skin it softens fine expression lines.
A longer cousin of Argireline, used on skin to soften forehead and eye lines.
Signals skin to rebuild collagen. Used in serums over time for firmness and fine lines.
A collagen-signal peptide for skin, often paired with Matrixyl.
Used on skin to raise collagen and hyaluronic acid production for a firmer, plumper look.
Kills the blood vessels feeding fat. It caused dramatic fat loss in animals and kidney damage with it.
The brain's wakefulness peptide, missing in people with narcolepsy. Studied as a nasal spray on limited data.
The two most popular healing peptides in one vial. 'Wolverine' is a community nickname, and ratios vary by vendor.
Two growth hormone signals in one injection, each working through a different receptor.
The same idea as the CJC-1295 and ipamorelin combo, using the older, shorter-acting sermorelin.
NAD+ 100 mg, MOTS-c 10 mg and 5-Amino-1MQ 10 mg in one vial. Two of the three are not peptides.
The only approved GLP-2 drug, for people with too little intestine. Not the 'GLP-2' sellers use to mean tirzepatide.
A GLP-1 drug approved for type 2 diabetes only. Weight loss is much smaller than people expect from this family.
The first GLP-1 drug, copied from Gila monster saliva. Still approved, and largely left behind by newer drugs.
The working part of parathyroid hormone. It builds new bone, where most osteoporosis drugs only slow the loss.
An antibody that blocks myostatin, tested with tirzepatide to lose less muscle along with the fat.
An antibody that blocks myostatin, tested with semaglutide so more of the weight lost is fat.
Designed to stick to a protein on cancer cells and punch holes in them. It has never been tested in a person.
Blocks a brake on the hair-growth signal Wnt. All published work is in mice, nearly all from the lab that invented it.
A copper peptide from the GHK-Cu family, sold mostly for hair, with far less research behind it.
Selank with both ends modified so enzymes break it down more slowly. Usually sold as a nasal spray.
Epitalon with its ends capped so enzymes take longer to break it down.
A Russian memory and focus drug taken by mouth. Not really a peptide, though it is sold beside Semax and Selank.
An extract of cattle or pig brain cortex, injected into muscle and used in Russia for brain recovery.
The five-amino-acid working part of a thymus hormone that helps immune cells mature.
A Russian six-amino-acid rework of thymopentin, with an arginine added at each end to make it last longer.
Makes mitochondria leak their charge as heat, so cells burn more for the same work. It has never been tested in people.
Not a peptideA 4-amino-acid Khavinson peptide sold for heart muscle and blood vessels, with very little human research.
A 4-amino-acid Khavinson peptide sold for liver support, with very little human research.
A 4-amino-acid Khavinson peptide sold for testosterone with age, with very little human research.
A 4-amino-acid Khavinson peptide sold for prostate support in older men, with very little human research.
A 3-amino-acid Khavinson peptide sold for immune balance, with very little human research.
A 4-amino-acid Khavinson peptide sold for pancreas function and blood sugar, with very little human research.
A 2-amino-acid Khavinson peptide sold for bladder lining support, with very little human research.
A calf pineal gland extract in capsules, sold for sleep and body clock, with very little human research.
A pancreas extract from young animals, sold for blood sugar and digestion, with very little human research.
A retina extract from young animals, sold for eyesight with age, with very little human research.
A bone marrow extract from young animals, sold for blood cell and immune recovery on very little human research.
A prostate extract from young animals, sold for prostate support in older men on very little human research.
An adrenal gland extract from young animals, sold for stress and cortisol balance on very little human research.
Meant to strengthen the tissue anchoring a hair follicle. Most of its evidence belongs to a combination product.
The GHK sequence with biotin attached in place of copper, used in hair, lash and brow products.
A piece of an immune protein with a fatty tail to cross skin. Used for calming, not collagen building.
Sold as Syn-Coll. Described as switching on a growth factor that drives collagen, a different route from Matrixyl.
A mimic of a temple viper venom component, sold for expression lines. Acts where the muscle receives the nerve signal.
The GHK sequence sold with no copper attached. A different product from GHK-Cu, because the copper is not inert.
A calf kidney extract sold in capsules as peptide complex A-9, marketed for kidney and urinary health.
A calf testicular extract sold in capsules as peptide complex A-13, marketed for male reproductive function.
A calf aorta extract sold in capsules as peptide complex A-3, marketed for vascular health and circulation.
One name sold for more than one molecule. Without a molecular weight or certificate, the label cannot say which.
A single-chain piece of the hormone relaxin, built to keep its anti-scarring activity and be simpler to make.
An eight-amino-acid brain peptide that stabilises the scaffolding inside neurons. Its main large human trial failed.
A frog-skin opioid that acts on the same receptor as morphine and is many times stronger.
A once-weekly GLP-1 from Sciwind Biosciences. It is approved in China and not in the US.
Myostatin itself, the growth factor that limits muscle. That is the opposite of what most buyers want.
A cattle retina extract developed in Russia and used in eye clinics there, from the same family as Cortexin.
A copy of the brain signal that controls sex hormones. An approved medicine, sold in the US as Trelstar and Triptodur.
The kidney hormone that tells bone marrow to make red blood cells. An approved medicine for anemia.
A calf thyroid extract sold in capsules as peptide complex A-2, marketed for thyroid function and energy.
A calf liver extract sold in capsules as peptide complex A-7, marketed for liver and gall bladder health.
A calf thymus extract sold in capsules as peptide complex A-6, marketed for immune function and aging.
A calf heart extract sold in capsules as peptide complex A-14, marketed for heart and cardiovascular health.
A calf stomach-lining extract sold in capsules as peptide complex A-10, marketed for digestion.
A calf muscle extract sold in capsules as peptide complex A-18, marketed for muscle performance and recovery.
An ovarian tissue extract sold in capsules as peptide complex A-15, marketed for menopause symptoms.
A calf parathyroid extract sold in capsules as peptide complex A-21, marketed for calcium balance and bone health.
A calf bladder-wall extract sold in capsules as peptide complex A-12, marketed for bladder control.
A calf lung and bronchial extract sold in capsules as peptide complex A-19, marketed for breathing.
Meant to soften expression lines by blocking the signal that tells a facial muscle to contract.
Modeled on enkephalin, and meant to quiet the nerve that tells a facial muscle to contract.
Targets slack skin along the jaw and neck, not fine lines, by acting on a protein linked to cell aging.
Slows the enzyme that makes skin pigment. Used on dark spots and uneven tone.
Blocks the hormone signal that tells skin cells to make pigment. Used on dark spots and uneven tone.
First found in yeast extract and now made synthetically. Sold for firmness, with little published to back it.
Used in eye creams for puffiness and bags, not for wrinkles.
A peptide with a fatty acid attached, used in lash and brow serums to support keratin production.
Epidermal growth factor, a 53-amino-acid human protein. A real growth signal, and far larger than its neighbors here.
From the same 1980s research program as GHRP-2 and GHRP-6, and the family member development moved past.
Banned by name on the WADA prohibited list. Beyond that, almost nothing is published about what it is.
A four-amino-acid peptide for the same receptor as GHRP-2 and GHRP-6, with no human research behind it at all.
A five-amino-acid member of the GHRP family. What is published about it stops at its molecular weight.
Copies the CagriSema idea in one vial. Neither half is approved, and the combination has never been trialled.
Semax, sold for focus, and Selank, sold for anxiety, in one vial or nasal spray.
A vendor name for TB-500, BPC-157 and KPV in one vial. It sits one component short of KLOW.
A name on vendor shelves beside Melanotan I and II. No published source says what molecule it refers to.
A name sold next to PT-141. No published source describes a distinct compound called PT-142.
A relative of the protein TB-500 comes from. Sold for repair, though the published work is on prostate tumor spread.
One of six small humanin-like peptides. Its research on insulin sensitivity and mitochondria is all in cells and mice.
Sold beside SHLP2 as if the two did the same thing. The published work points in a different direction.
A myostatin relative once reported to rejuvenate old tissue. Follow-up studies have been arguing about it ever since.
A peptide the body makes, linked to insulin sensitivity and fatty liver. Known from measuring it, not from giving it.
A fragment muscle releases during exercise, reported to turn white fat brown. The blood tests for it proved unreliable.
Found by searching genome databases. Animal work links it to appetite and weight, with no human trial of giving it.
A four-amino-acid antibody fragment that stimulates the cells that engulf bacteria. Selank was built from it.
A short fragment of a spleen protein, sold for immune support. The research is old, thin and hard to retrieve.
Switches on AMPK, the cell's low-energy sensor. The amounts in the famous animal studies do not scale to a person.
Not a peptideActs on the body clock and is sold as exercise in a capsule. Published work found it is barely absorbed by mouth.
Not a peptideAn abandoned metabolic drug. Animal testing found tumors across multiple organs, and it is still sold for endurance.
Not a peptideA pill that raises appetite and lean mass in cancer wasting. Approved in Japan, and US regulators were not convinced.
Not a peptideGiven once by mouth, as a test of whether the pituitary can release growth hormone. Nobody takes it repeatedly.
Not a peptideA daily GLP-1 for type 2 diabetes. A real approved drug that was outsold and withdrawn from the US market.
A weekly GLP-1 approved in 2014. Less effective than rivals and mixed before every injection, so its maker pulled it.
The human GLP-1 hormone itself, not a modified copy, so it is injected three times a day. Approved in China.
Floods the switch that controls sex hormones until it stops responding, shutting hormone production down.
The same hormone shutdown as leuprolide, delivered as a pellet under the skin that dissolves over weeks.
Used during IVF to block the signal that triggers ovulation, so eggs can be collected on schedule.
Drops testosterone immediately in advanced prostate cancer, without the surge the older drugs cause first.
A modified vasopressin that tells the kidneys to hold on to water. It also treats bleeding disorders.
Builds new bone the way teriparatide does, from a different parent hormone. Approved for osteoporosis.
Lowers blood calcium and slows bone breakdown. Approved for osteoporosis, and the least effective drug in that space.
Stops the brain seeing estrogen, so it tells the testicles to make more testosterone. One of clomiphene's two isomers.
Not a peptideBlocks estrogen feedback in the brain. That triggers ovulation in women and raises testosterone in men.
Not a peptideBlocks estrogen in breast tissue. Used against breast cancer and against breast tissue growth in men.
Not a peptideStops the body making estrogen in the first place, so levels fall. It does not block the receptor.
Not a peptideShuts down estrogen production more completely than anastrozole does.
Not a peptideA close relative of tamoxifen for breast cancer. It also stretches out the heart's electrical cycle.
Not a peptideTells the pituitary to stop releasing prolactin. Approved for disorders of high prolactin.
Not a peptideA bile acid that helps bile flow and takes strain off liver cells. Taken alongside things that are hard on the liver.
Not a peptideA compounded shot of methionine, inositol and choline, usually with B12. Given weekly at clinics as a fat-loss aid.
Not a peptideThe shuttle that carries fat into the part of the cell that burns it.
Not a peptideMade by gut bacteria from pomegranates, walnuts and berries. Tells cells to clear out worn-out mitochondria.
Not a peptideRaw material the body uses to make NAD+, one step closer to it than nicotinamide riboside.
Not a peptideA form of vitamin B3 the body turns into NAD+, one step further back than NMN. It is sold mostly as Niagen.
Not a peptideThe first four residues of TB-500, and something the body already makes. Its anti-scarring effects are in animal models.
Taken by mouth to hold on AMPK, the switch the body normally flips during exercise or fasting.
Not a peptideA lab-built version of fisetin, a strawberry compound, developed at the Salk Institute and aimed at brain aging.
Not a peptideA sedative for the same receptor as baclofen, still prescribed in Russia and Latvia. Tolerance builds quickly.
Not a peptideA synthetic dipeptide that blocks the receptor that triggers panic, instead of damping the brain down like a sedative.
A protein the body makes less of with age. Mice given more of it live longer.
Sold as a cleaner successor to MK-677, also called Acetamoren. There is no published research on it at all.
Marketed as follistatin that lasts longer in the body. What is actually in the vial is unverified.
BPC-157, TB-500 and Cartalax in one vial, typically 10 mg of each. Sold as Regeno and as Deadpool. The third is aimed at cartilage.
Semax with an acetyl group on one end, added to slow how fast the body breaks it down.
The copper-free cousin of AHK-Cu, with a fatty tail to get through skin. Sold in scalp and lash serums on thin evidence.
A copy of collagen's most common three-amino-acid unit. Plausible in theory, with almost no published human evidence.
From the same p53 program as PNC-27. It worked in dishes and mice, and no published study has given it to a person.
Raises dopamine and protects dopamine cells in cell and animal studies. No human has been studied taking it.
Not a peptideA family name for any peptide with a fatty tail, not one compound. Two products so labeled can be different molecules.
The older cousin of the CJC-1295 and ipamorelin blend, with GHRP-2 in ipamorelin's place.
The compound behind the 'GLP-4' label on injectable vials. The real thing is an experimental once-daily capsule.
An 11-amino-acid piece cut from the precursor of GDNF, tested for protecting dopamine neurons.
A fragment left when the body breaks down oxytocin. It acts on dopamine receptors and behaves nothing like its parent.
An engineered follistatin injected into one muscle. Trials showed a bigger muscle and nobody any stronger.
Alagebrium, meant to break the sugar-protein crosslinks that stiffen tissue with age.
Not a peptideFound by screening compounds in live mice for anything that kept newborn brain cells alive. Works by raising NAD levels.
Not a peptideThe pharmacy-aisle vitamin for nerves and red blood cells, sold by peptide vendors in a research vial.
Not a peptideSold as a Selank relative. One seller describes N-Acetyl Selank Amidate, and the others state no structure.
The brain's signal to the thyroid chain. Its approved form was a single test injection, now discontinued.
A generic name for pig-brain peptide mixtures used in hospitals in India and China. A vendor's vial is none of those.
The Adamax that weighs about 1032: Semax with an acetyl group on one end and an adamantane group on the other.
Selank with an acetyl cap on one end. N-Acetyl Selank Amidate is a different product, with an amide on the other end.
The Adamax that weighs about 984: acetylated Semax with two extra amino acids and no adamantane group.
The main component of Alzheimer's plaques, bought by researchers to model that damage. Nobody takes it for a benefit.
Hengrui and Kailera's weekly GLP-1/GIP shot, built to beat tirzepatide and now in global phase 3.
Merck's weekly GLP-1/glucagon agonist for fatty liver disease, an oxyntomodulin copy fused to an antibody tail.
A GLP-1/GIP prodrug built to release slowly enough for one shot a month. Phase 1, eight people's worth of data.
Hengrui and Kailera's triple agonist, a different molecule from retatrutide, with 12-week phase 1 data.
The single peptide in Matrixyl synthe'6: a palmitoyl tripeptide with an oxidised methionine, sold at parts per million.
A cone-snail venom peptide approved for severe pain, given only by pump into the spinal fluid, with a boxed warning for psychiatric effects.
The lupus peptide that passed phase 2 and missed phase 3, now awaiting a higher-dose redesign that has not started.
A 4 kDa bicyclic peptide carrying a chemotherapy payload to bladder cancer cells. Deprioritised by its developer in March 2026.
A seven-residue Drp1 fragment that blocks stress-driven mitochondrial splitting in mice. Never given to a person.
A bacterial peptide antibiotic found by genome mining that kills resistant Gram-negative bacteria in mice. Preclinical, with nothing for sale.
Pfizer's long-acting GLP-1 shot from the Metsera deal, tested weekly and monthly and now in phase 3.
Antag's GIP receptor blocker, tested on top of semaglutide to see whether blocking GIP adds weight loss.
Shionogi's IV fragment of the HMGB1 protein, meant to call the body's own stem cells to damaged tissue.
An FDA-approved somatostatin copy that shuts down growth hormone, used for acromegaly and hormone-secreting tumors.
An FDA-approved capsule peptide that stays in the gut and draws water into the bowel to treat constipation.
Pfizer's ultra-long-acting amylin analog from the Metsera deal, built for monthly dosing alongside berobenatide.
An FDA-approved vasopressin prodrug for a kidney failure that strikes people with advanced liver disease.
A ghrelin-mimicking pentapeptide built to speed stomach emptying in gastroparesis, dropped in 2020.
EndoCyclic's non-hormonal peptide for endometriosis, cleared for a first human trial in March 2026.
A frog-peptide antibiotic cream for infected diabetic foot ulcers that failed FDA review in 1999 and phase 3 in 2016.
A cyclic peptide that blocks the brain's appetite brake, in phase 2 to prevent weight loss during cancer chemotherapy.
Kalohexis's oral peptide that switches on both the MC3 and MC4 appetite receptors, now in a phase 1 for obesity.
The first FDA-approved Rett syndrome drug: a modified three-amino-acid fragment from the start of IGF-1, taken by mouth.
An FDA-approved bradykinin blocker that patients inject themselves to stop hereditary angioedema attacks.
Octreotide's longer-acting cousin: a somatostatin copy given as a monthly depot for acromegaly and neuroendocrine tumors.
An EU-approved liposomal immune stimulant added to chemotherapy for bone cancer in children and young adults.
The first HIV fusion inhibitor: a 36-amino-acid twice-daily shot, approved in 2003 and withdrawn from the US in 2025.
A cyclic lipopeptide antibiotic from soil bacteria, approved since 2003 for serious staph skin and bloodstream infections.
Gan & Lee's once-weekly GLP-1 tablet, a peptide rather than a small molecule, in its first human trial since September 2026.
BASF's Syniorage peptide for firmer mature skin: four amino acids from a pig antimicrobial protein, backed by supplier data only.
The first targeted peptide pill for psoriasis: it blocks the IL-23 receptor and was approved in the US in March 2026.
The first PCSK9 pill: a three-ring peptide that cut LDL cholesterol by 56 to 59% on top of statins, approved in the US in July 2026.
Lutathera's peptide carrying actinium-225 instead of lutetium; its phase 3 beat standard care in tumors that regrew after lutetium.
A somatostatin-like peptide carrying radioactive lutetium-177 into neuroendocrine tumors, approved since 2017 in Europe and 2018 in the US.
A stroke drug approved only in India: a 14-residue fragment of endothelin-1 that switches on the B receptor, now in a US phase 3.
A stroke neuroprotectant that missed its main goal in three large trials; a case study in subgroup findings that did not survive retesting.
Linaclotide's rival: a copy of the gut hormone uroguanylin with one change, approved for chronic constipation and IBS with constipation.
The third approved somatostatin analog: it hits more receptor types than octreotide or lanreotide, and raises blood sugar in most users.
Ascletis's amylin peptide, made as a monthly depot injection and a daily tablet; both entered US phase 1 trials in 2026.
A soothing cosmetic peptide sold as Neutrazen: a fatty-tailed piece of alpha-MSH aimed at redness and sensitive skin.
The GLP-1 drugs in reverse: a peptide that blocks the GLP-1 receptor to stop dangerous blood sugar crashes after gastric bypass.
A once-weekly parathyroid hormone for people whose parathyroid glands do not work, now in a phase 3; the approved options are daily.
The first treatment for hepatitis delta: a fatty-tailed copy of part of the hepatitis B virus that blocks its door into liver cells.
An approved itch treatment for people on dialysis: a four-residue mirror-image peptide that works on opioid receptors outside the brain.
A daily self-injected peptide for myasthenia gravis that blocks complement protein C5, the same target as the antibody eculizumab.
Two copies of a complement-blocking peptide on a long PEG chain, approved for a rare blood disease, two kidney diseases and, in the US and Australia, an eye disease.
A copy of the fat hormone leptin for people with almost no body fat. Approved for lipodystrophy, and ruled out by its label for ordinary obesity.
A skin-firming cosmetic peptide sold as Biopeptide EL: a fatty-tailed copy of a repeating stretch of elastin, backed by one small supplier study.
An experimental cell-penetrating peptide that blocks beta-catenin, the switch behind desmoid tumors and the polyps of familial adenomatous polyposis.
An experimental peptide from Sapience that stops beta-catenin binding BCL9, tested in colorectal cancer and planned for FAP.
An experimental mirror-image peptide that dismantles the cancer-linked protein C/EBP-beta, being tested in glioblastoma.
A cyclic peptide that stops platelets clumping, given by drip during heart attacks and stent procedures. Designed from a rattlesnake venom protein.
A 20-residue thrombin blocker modeled on the leech anticoagulant hirudin, given by drip during angioplasty and stenting.
The body's own blood-pressure hormone, given by drip in intensive care to raise blood pressure in septic shock.
An oxytocin blocker used in Europe to delay premature labor for up to 48 hours. Never approved in the US.
A long-acting oxytocin given once after birth to prevent heavy bleeding. Heat-stable, on the WHO essential list, not approved in the US.
An every-two-weeks GLP-1 injection from Gan & Lee, nearly identical to semaglutide. In phase 3 in China and licensed to Menarini for Europe.
A weekly GLP-1 and glucagon injection for fatty liver disease: a small peptide on a large PEG, close to efinopegdutide. Phase 2 so far.
An investigational IV peptide adapted from an astrovirus coat protein that blocks complement at C1q and the neutrophil enzyme myeloperoxidase, now in phase 2 trials.
An experimental five-amino-acid mimic of apolipoprotein E, given by drip in the hospital after brain bleeds and around surgery; no trial has yet shown benefit.
An investigational eye drop made from a 19-residue fragment of lacritin, a natural tear protein, now in phase 2 for neurotrophic keratitis.
A daily IVF injection that keeps eggs from being released before collection; in 1999 it became the first GnRH antagonist the FDA approved.
The first 24 amino acids of ACTH, injected once to test whether the adrenal glands can make cortisol; FDA-approved as a diagnostic since 1970.
A synthetic copy of the gut hormone that makes the pancreas release bicarbonate, injected once to test pancreatic function and detect gastrin-making tumors.
A once-weekly injection for children with achondroplasia that slowly releases natural-sequence CNP, a growth-plate signal. FDA-approved under accelerated approval in February 2026.
A daily injection that mimics CNP, a growth-plate signal, to speed growth in children with achondroplasia; under FDA accelerated approval since November 2021.
A twice-weekly GLP-2 injection from Zealand Pharma for short bowel syndrome, recommended for EU approval in September 2026; the FDA wants another trial.
A once-weekly GLP-2 injection for short bowel syndrome whose phase 3 met its main goal, though the FDA wants a second trial, now recruiting.
A daily parathyroid hormone replacement for adults with hypoparathyroidism, built as a prodrug that slowly releases teriparatide; FDA-approved in August 2024.
A ready-to-use glucagon analog for severe low blood sugar in diabetes that worked in a median 10 minutes in trials; now discontinued in the US.
A weekly injection that switches on the platelet hormone's receptor to raise platelet counts in immune thrombocytopenia, using an antibody fragment that carries four copies of a 14-residue peptide.
A lab-made copy of the heart's own BNP hormone, dripped into a vein for acute heart failure from 2001 until US sales ended in 2020.
A cosmetic peptide mimicking decorin, a skin protein that orders collagen; alone, it was not significantly better than placebo in its one independent trial.
A weekly injection that copies hepcidin, the body's iron-control hormone, to keep red cell levels down in polycythemia vera; FDA-approved in August 2026.
The FDA-approved form of the body's own IGF-1, injected twice daily for children with severe primary IGF-1 deficiency; IGF-1 LR3 and DES are different molecules.
A once-yearly arm implant that pauses early puberty in children by switching off the pituitary signal to the ovaries or testes.
A synthetic piece of the gut hormone cholecystokinin, injected into a vein to make the gallbladder contract during scans and pancreas tests.
An experimental injected peptide for the lung scarring of idiopathic pulmonary fibrosis, tested so far only in healthy volunteers and in mice.
An experimental oral peptide from Protagonist that blocks IL-17A and IL-17F, aimed at psoriasis; it has completed only a phase 1 in healthy volunteers.
The natural hormone used as emergency rescue for severe low blood sugar, now sold in the US as Baqsimi nasal powder, Gvoke and generic kits.
A gut hormone that weakly activates GLP-1 and glucagon receptors, the parent of mazdutide; never developed as a drug, with only small short human studies.
A weekly PYY analog from Novo Nordisk, tested as an add-on to semaglutide for obesity; it added little weight loss and was dropped in 2023.
A five-amino-acid ring peptide from Merck KGaA that blocks integrins on tumor blood vessels; it failed a 545-patient glioblastoma phase 3 in 2013.
A synthetic peptide that gels on contact with blood, used by endoscopists and surgeons to seal oozing vessels; FDA-cleared as a device, not a drug.
A thymopentin fragment sold as Thymulen 4 for skin regeneration and as Uplevity for firming; its only independent study used cultured skin cells.
A Lubrizol hydration peptide said to boost aquaporin-3 water channels in skin; its 131% hydration claim comes with no published panel or method.
A dialysis drug that tricks the parathyroid glands' calcium sensor into making less parathyroid hormone, given into the dialysis line three times a week.
The body's own water-holding hormone, given by drip in intensive care to raise blood pressure in shock when fluids and other drugs are not enough.
A modified GnRH sprayed into the nose that shuts down sex hormone production, approved in the US for endometriosis and early puberty in children.
A 10-amino-acid peptide built on a piece of the T-cell protein CD28, given once into a vein for flesh-eating infections; never approved, and its developer reportedly closed in 2022.
A modified dipeptide that keeps cells coupled through gap junctions; it failed in heart attacks and is now being developed by mouth for diabetic eye disease.
Plecanatide with mirror-image amino acids at both ends; its maker reported it met its goal in a 292-patient opioid constipation trial, then stalled, with no news since 2020.
A BASF soothing peptide for sensitive skin, built from the opioid peptide endomorphin-2; every efficacy claim comes from the supplier, with no numbers published.
A once-weekly experimental injection from The United Laboratories, licensed to Novo Nordisk, that acts on GLP-1, GIP and glucagon receptors for weight loss.
A one-carbon variant of cyclosporine approved in 2021 for lupus nephritis, taken as capsules twice daily with mycophenolate and carrying a boxed warning.
A fungal ring peptide that switches off T cells, approved since 1983 against transplant rejection and best known today as Restasis and other dry-eye drops.
An oral analog of the brain hormone TRH, approved in Japan and South Korea for loss of coordination in spinocerebellar degeneration, with small measured benefits.
A recombinant copy of the human hormone relaxin-2, infused for 48 hours in acute heart failure; it failed a 6,600-patient trial in 2017.
The stomach's own hunger hormone, a 28-residue peptide with a fatty chain and the natural key to the ghrelin receptor; tested in small trials, never approved.
The liver's own blocker of the ghrelin receptor; infused into 40 men in two single-day studies, it cut eating at one meal by about 12%.
A 12-amino-acid antimicrobial peptide gel tested to prevent catheter infections and treat rosacea; both catheter phase 3 trials missed, and it was never approved.
A 23-residue piece of thrombin sold for fracture and wound healing. Its 503-patient phase 3 failed, and every human dose was micrograms, given locally.
A lactoferrin fragment laid around repaired hand tendons to stop scar gluing them down. Its one randomized trial missed its primary endpoint; the program closed in 2023.
An experimental brain-tumor vaccine: a 14-residue piece of a mutant receptor tied to a mollusk protein. Its 745-patient phase 3 failed in 2016.
A nine-residue piece of HER2 injected with an immune stimulant to stop breast cancer returning. Its 758-patient phase 3 was stopped for futility.
A 16-residue telomerase fragment tested as a cancer vaccine. South Korea approved it in 2014 for pancreatic cancer and canceled that approval in 2020.
The natural beta-cell hormone every amylin drug copies, undruggable because its own residues 25 to 29 turn it into the amyloid found in diabetic islets.
Protagenic's injected stress peptide, through phase 1 in healthy volunteers, with no sequence disclosed, no published data and a sponsor short of cash.
A bacterial seven-residue double ring that kills resistant Gram-negative bacteria by jamming BamA. No person has ever received it and no company is developing it.
The most-used peptide in a 2021 survey of 88 sensitive-skin face products, sold as Calmosensine; its one peer-reviewed human test did not beat a competitor's ingredient.
The only peptide in the MOTS-c family with finished human results. It completed phase 1, moved liver fat no better than placebo, and the company then said its formulation could not be developed further.
A mitochondrial microprotein named in July 2026. A start-codon variant that would switch it off is tied to type 2 diabetes in Mexican American cohorts.
A 58-amino-acid mitochondrial microprotein. A variant that changes one of its residues carries about 30% more Alzheimer's risk, and roughly a quarter of people of European ancestry have it.
A nine-amino-acid ring peptide that opens a transport route into tumors so chemotherapy can follow it in. Its 158-patient pancreatic cancer trial missed its main endpoint in the larger cohort and fell short of significance in the smaller one.
A melanocortin eye drop for dry eye. Its 575-patient phase 3 missed both co-primary endpoints as planned, and hit one only after the analysis was adjusted for age and sex.
A seven-residue cyclic MC1R peptide in a capsule that releases in the colon. Its ulcerative colitis trial stopped at 12 patients, and the company reported a p-value from a study it called underpowered.
Ascletis's triple agonist, built as a weekly tablet and a monthly depot injection. Mouse and monkey data only, with INDs expected by the end of 2026.
A three-amino-acid hair peptide from Amorepacific, in COSRX hair products. The parent company says tensile strength rises up to 44%; the brand's own page says 11.1%.
A 21-residue peptide for Huntington's disease that binds the repeat RNA itself. FDA orphan designation in August 2026. No paper names this candidate, but the university peptide it came from is published, with a sequence.
A 58-residue cow protein that cuts bleeding in heart surgery. Pulled worldwide in 2007 over a mortality signal, then reinstated in Europe after regulators judged that study unreliable.
A kidney version of the heart's ANP hormone, infused for 48 hours in acute heart failure. In a 2,157-patient trial it eased congestion and changed survival not at all.
Human ANP itself, made in a lab and approved in Japan since 1995. The one trial built to test its effect on long-term outcomes stopped early, and pooled data point the wrong way on survival.
Two natriuretic peptides welded together: the CNP ring plus a snake venom peptide's tail, built to hit two receptors at once and lower blood pressure less.
A triple agonist that swaps glucagon for a different third target: the NPY2 receptor. A 344-person dose-finding trial is running, and no efficacy number has ever been published.
A four-residue skin peptide aimed at lumican, a proteoglycan that organizes collagen. The supplier's own human study was 17 women with no control group.
Everyone calls it a glycopeptide, and the FDA's own substance registry files it as a chemical with no sequence. Swallowed it barely leaves the gut, and that is why the capsule and the drip treat different infections.
Not a peptideGastrin's four-residue business end with a chemical handle on the front, injected to make the stomach pour acid during a test. Approved in 1974 and off the market since 2002.
A 13-residue brain and gut peptide, discovered because it dropped blood pressure in animals. It tangles with dopamine signaling, clears from blood in about four minutes, and is not a treatment for anything.
Gilead agreed to pay $1.275 billion in upfront cash for this oral IL-23 receptor peptide in October 2026. Not one number about how well it works has ever been published.
A once-monthly GLP-1 and GIP dual agonist from Ascletis. Every comparison with tirzepatide so far comes from mice, monkeys or a test tube.
A collagen-style cosmetic peptide sold as Collaxyl. The 2025 wrinkle trial everyone cites for it tested a different molecule, and that paper's own data say this one is destroyed on contact with collagenase.
Announced in 2015 under the title 'kills pathogens without detectable resistance'. In 2025 a laboratory produced teixobactin-resistant Staphylococcus aureus that was also multidrug resistant. Still never given to a human.
The gut hormone behind every PYY analog on this site. Infused into a vein it cuts food intake by about 30 percent. Injected under the skin it did nothing at all.
A heart and vessel hormone that lowers blood pressure and raises cardiac output in people. Four drug programs have tried to use it. The two that got furthest were both terminated.
A stress-hormone relative that acts on CRF2 rather than CRF1. A four-hour infusion in 53 acute heart failure patients dropped blood pressure and raised cardiac output by over half.
The apelin receptor's second natural hormone, found twice by two labs that gave it two different names. Never given to a human, and it has no FDA substance record at all.